600557 康缘药业
已收盘 12-11 15:00:00
资讯
新帖
简况
甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围
证券之星 · 12-10 09:22
甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围
康缘药业(600557)披露公司部分药品纳入《国家医保目录》,12月9日股价下跌1.42%
证券之星 · 12-09 17:47
康缘药业(600557)披露公司部分药品纳入《国家医保目录》,12月9日股价下跌1.42%
康缘药业:12月4日高管潘宇、陈学斌增持股份合计1.1万股
证券之星 · 12-08 20:03
康缘药业:12月4日高管潘宇、陈学斌增持股份合计1.1万股
康缘药业最新公告:独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片纳入《国家医保目录》
证券之星 · 12-08
康缘药业最新公告:独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片纳入《国家医保目录》
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
智通财经网 · 12-08
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
康缘药业:12月3日高管潘宇增持股份合计2000股
证券之星 · 12-05
康缘药业:12月3日高管潘宇增持股份合计2000股
康缘药业:12月1日高管杨永春、刘权增持股份合计1.19万股
证券之星 · 12-03
康缘药业:12月1日高管杨永春、刘权增持股份合计1.19万股
供需两旺!康缘药业呼吸产品矩阵迎流感高峰 中成药成防控“主力”
证券之星 · 12-02
供需两旺!康缘药业呼吸产品矩阵迎流感高峰 中成药成防控“主力”
康缘药业:11月27日至11月28日高管潘宇、陈学斌增持股份合计5000股
证券之星 · 12-01
康缘药业:11月27日至11月28日高管潘宇、陈学斌增持股份合计5000股
流感高发季 康缘药业金振口服液需求明显提升
证券之星 · 11-26
流感高发季 康缘药业金振口服液需求明显提升
康缘药业:11月20日至11月21日高管刘权、潘宇、王传磊、陈学斌增持股份合计2.03万股
证券之星 · 11-24
康缘药业:11月20日至11月21日高管刘权、潘宇、王传磊、陈学斌增持股份合计2.03万股
每周股票复盘:康缘药业(600557)实控人肖伟增持2万股,耗资32.52万元
证券之星 · 11-23
每周股票复盘:康缘药业(600557)实控人肖伟增持2万股,耗资32.52万元
康缘药业:11月11日至11月19日高管杨永春、高海鑫、刘权、王传磊、潘宇增持股份合计5.54万股
证券之星 · 11-20
康缘药业:11月11日至11月19日高管杨永春、高海鑫、刘权、王传磊、潘宇增持股份合计5.54万股
甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围
证券之星 · 11-20
甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围
11月18日增减持汇总:康缘药业增持 高德红外等15股减持(表)
新浪证券 · 11-18
11月18日增减持汇总:康缘药业增持 高德红外等15股减持(表)
康缘药业最新公告:实际控制人、董事肖伟增持公司股份2万股
证券之星 · 11-18
康缘药业最新公告:实际控制人、董事肖伟增持公司股份2万股
每周股票复盘:康缘药业(600557)实控人一致行动人增持8万股
证券之星 · 11-16
每周股票复盘:康缘药业(600557)实控人一致行动人增持8万股
11月12日康缘药业发布公告,股东增持8万股
证券之星 · 11-12
11月12日康缘药业发布公告,股东增持8万股
每周股票复盘:康缘药业(600557)多名高管拟增持不低于12万股
证券之星 · 11-09
每周股票复盘:康缘药业(600557)多名高管拟增持不低于12万股
康缘药业(600557.SH)部分董高层拟合计增持不低于12万股公司股份
智通财经 · 11-07
康缘药业(600557.SH)部分董高层拟合计增持不低于12万股公司股份
加载更多
公司概况
公司名称:
江苏康缘药业股份有限公司
所属行业:
医药制造业
上市日期:
2002-09-18
主营业务:
江苏康缘药业股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是金振口服液、热毒宁注射液、杏贝止咳颗粒、温阳解毒颗粒、银杏二萜内酯葡胺注射液、天舒胶囊、天舒片、龙血通络胶囊、桂枝茯苓胶囊、散结镇痛胶囊、复方南星止痛膏、腰痹通胶囊、筋骨止痛凝胶、参乌益肾片、济川煎颗粒。公司是国家技术创新示范企业、国家重点高新技术企业、国家创新型试点企业、国家知识产权示范企业,全国制药工业百强企业。公司积极实施创新驱动战略,建立了国际先进的创新药物研发体系,在新药研发、有效发明专利、承担国家重大科研项目的数量上均居行业领先水平。
发行价格:
7.00
{"stockData":{"symbol":"600557","market":"SH","secType":"STK","nameCN":"康缘药业","latestPrice":15.15,"timestamp":1765436400000,"preClose":15.19,"halted":0,"volume":6082042,"delay":0,"changeRate":-0.0026,"floatShares":566000000,"shares":566000000,"eps":0.414,"marketStatus":"已收盘","change":-0.04,"latestTime":"12-11 15:00:00","open":15.16,"high":15.39,"low":15.06,"amount":92434800,"amplitude":0.0217,"askPrice":15.16,"askSize":171,"bidPrice":15.15,"bidSize":633,"shortable":0,"etf":0,"ttmEps":0.414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765503000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.19,"symbolType":"stock","openAndCloseTimeList":[[1765416600000,1765423800000],[1765429200000,1765436400000]],"highLimit":16.71,"lowLimit":13.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":566158806,"isCdr":false,"pbRate":1.82,"roa":"--","peRate":36.594203,"roe":"4.33%","epsLYR":0.68,"committee":0.00754,"marketValue":8577000000,"turnoverRate":0.0107,"status":1,"floatMarketCap":8577000000},"requestUrl":"/m/hq/s/600557","defaultTab":"news","newsList":[{"id":"2590737659","title":"甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2590737659","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590737659?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:22","pubTimestamp":1765329762,"startTime":"0","endTime":"0","summary":"近日,康缘药业在投资者互动平台回应市场关切时明确表示,公司核心产品金振口服液凭借“儿童专用+疗效确切”的差异化优势,在本轮甲流疫情中销量实现显著增长,驱动公司业绩稳健增长。销量持续攀升拉动业绩增长康缘药业在回应中披露的经营数据显示,金振口服液的市场表现已成为公司业绩增长的“压舱石”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025121000006110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600557","BK0239"],"gpt_icon":0},{"id":"2590231443","title":"康缘药业(600557)披露公司部分药品纳入《国家医保目录》,12月9日股价下跌1.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590231443","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590231443?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:47","pubTimestamp":1765273643,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘,康缘药业报收于15.24元,较前一交易日下跌1.42%,最新总市值为86.28亿元。该股当日开盘15.43元,最高15.55元,最低15.23元,成交额达1.02亿元,换手率为1.17%。近日,江苏康缘药业股份有限公司发布公告称,根据国家医保局于2025年12月7日发布的《国家医保目录》,公司独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片首次通过谈判纳入目录。公司共有123个品种纳入《国家医保目录》,其中甲类48个,乙类75个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900027745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600557","BK0239","BK0188"],"gpt_icon":0},{"id":"2589370033","title":"康缘药业:12月4日高管潘宇、陈学斌增持股份合计1.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589370033","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589370033?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:03","pubTimestamp":1765195395,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月8日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年12月4日公司高级管理人员潘宇、董事陈学斌共增持公司股份1.1万股,占公司总股本为0.0019%。变动期间公司股价下跌0.2%,12月4日当日收盘报15.1元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800029551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","600557"],"gpt_icon":0},{"id":"2589334845","title":"康缘药业最新公告:独家品种温阳解毒颗粒、玉女煎颗粒及国内首家仿制药品种舒马普坦萘普生钠片纳入《国家医保目录》","url":"https://stock-news.laohu8.com/highlight/detail?id=2589334845","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589334845?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:39","pubTimestamp":1765190374,"startTime":"0","endTime":"0","summary":"康缘药业(600557.SH)公告称,公司独家品种温阳解毒颗粒、玉女煎颗粒,以及国内首家仿制药品种舒马普坦萘普生钠片首次通过谈判纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年版)》。其中,温阳解毒颗粒和玉女煎颗粒为中药新药,分别用于治疗疫病辨证属阳气虚弱和胃热阴虚证;舒马普坦萘普生钠片为化学药品3类,用于成人有或无先兆偏头痛的急性治疗。此次纳入医保预计将推动公司新药市场推广与销售增长,但对公司业绩的短期影响暂无法估计。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800024584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600557","BK0239"],"gpt_icon":0},{"id":"2589803385","title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2589803385","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589803385?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:31","pubTimestamp":1765164685,"startTime":"0","endTime":"0","summary":"根据国家医保局披露的名单,此次新增的6个中成药品种分别为:温阳解毒颗粒、参郁宁神片、养血祛风止痛颗粒、益气清肺颗粒、玉女煎颗粒、芪防鼻通片,其中包括3个1.1类新药,3个3类新药。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0188","BK0012","BK0185","603998","BK0060","002603","BK0097","BK0010","BK0183","BK0196","BK0239","BK0042","BK0046","BK0028","000999","BK0175","600557"],"gpt_icon":0},{"id":"2589695894","title":"康缘药业:12月3日高管潘宇增持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589695894","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589695894?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:03","pubTimestamp":1764936184,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月5日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年12月3日公司高级管理人员潘宇共增持公司股份2000.0股,占公司总股本为0.0004%。康缘药业近半年内的董监高及核心技术人员增减持详情如下:康缘药业的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入440.42万,融资余额增加;融券净流出2.5万,融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500034769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0188","BK0028"],"gpt_icon":0},{"id":"2588045809","title":"康缘药业:12月1日高管杨永春、刘权增持股份合计1.19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045809","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588045809?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:03","pubTimestamp":1764763400,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月3日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年12月1日公司董事,高级管理人员杨永春、高级管理人员刘权共增持公司股份1.19万股,占公司总股本为0.0021%。康缘药业近半年内的董监高及核心技术人员增减持详情如下:康缘药业的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入55.41万,融资余额增加;融券净流出4.9万,融券余额减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300034922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0028","BK0188"],"gpt_icon":0},{"id":"2588036230","title":"供需两旺!康缘药业呼吸产品矩阵迎流感高峰 中成药成防控“主力”","url":"https://stock-news.laohu8.com/highlight/detail?id=2588036230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588036230?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:22","pubTimestamp":1764667353,"startTime":"0","endTime":"0","summary":"康缘药业在投资者互动平台中透露,公司呼吸与感染疾病产品线已形成完整矩阵,覆盖从预防到治疗、从儿童到成人的多类症状需求。事实上,康缘药业近年来着力构建的呼吸与感染疾病产品矩阵正在此轮疾病高峰中发挥协同效应。康缘药业通过多年来在呼吸系统疾病领域的产品布局与临床投入,已在当前疾病高发期展现出强劲的产品能力与市场应变能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025120200025671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2588722887","title":"康缘药业:11月27日至11月28日高管潘宇、陈学斌增持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722887","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588722887?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:02","pubTimestamp":1764590568,"startTime":"0","endTime":"0","summary":"证券之星消息,根据12月1日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年11月27日至2025年11月28日公司高级管理人员潘宇、董事陈学斌共增持公司股份5000.0股,占公司总股本为0.0009%。变动期间公司股价下跌2.46%,11月28日当日收盘报15.08元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100030975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600557","BK0188","BK0028"],"gpt_icon":0},{"id":"2586853242","title":"流感高发季 康缘药业金振口服液需求明显提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2586853242","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586853242?lang=zh_cn&edition=full","pubTime":"2025-11-26 09:10","pubTimestamp":1764119409,"startTime":"0","endTime":"0","summary":"针对这一临床痛点,康缘药业于2023年公布的金振口服液联合阿奇霉素治疗儿童肺炎支原体肺炎的循证医学研究,提供了新的解决方案。基于在支原体肺炎领域建立的高级别证据,康缘药业正尝试进一步拓展金振口服液的适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025112600004672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","600557"],"gpt_icon":0},{"id":"2585461979","title":"康缘药业:11月20日至11月21日高管刘权、潘宇、王传磊、陈学斌增持股份合计2.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461979","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585461979?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:01","pubTimestamp":1763985708,"startTime":"0","endTime":"0","summary":"证券之星消息,根据11月24日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年11月20日至2025年11月21日公司高级管理人员刘权、高级管理人员潘宇、高级管理人员王传磊、董事陈学斌共增持公司股份2.03万股,占公司总股本为0.0037%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400030292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2585108005","title":"每周股票复盘:康缘药业(600557)实控人肖伟增持2万股,耗资32.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108005","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108005?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:01","pubTimestamp":1763834475,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,康缘药业报收于14.84元,较上周的16.39元下跌9.46%。本周关注点来自股本股东变化:实控人肖伟增持2万股,耗资32.52万元来自公司公告汇总:本次增持后,肖伟及其一致行动人持股比例升至36.6859%股本股东变化2025年11月17日,公司董事肖伟增持股份2.0万股,占总股本0.0035%,期间股价下跌2.81%,11月17日收盘报15.93元。本次增持后,肖伟及其一致行动人合计持股比例由36.6824%增至36.6859%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600557","BK0239"],"gpt_icon":0},{"id":"2584136443","title":"康缘药业:11月11日至11月19日高管杨永春、高海鑫、刘权、王传磊、潘宇增持股份合计5.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584136443","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584136443?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:01","pubTimestamp":1763640110,"startTime":"0","endTime":"0","summary":"证券之星消息,根据11月20日市场公开信息、上市公司公告及交易所披露数据整理,康缘药业最新董监高及相关人员股份变动情况:2025年11月11日至2025年11月19日公司董事,高级管理人员杨永春、董事高海鑫、高级管理人员刘权、高级管理人员王传磊、高级管理人员潘宇共增持公司股份5.54万股,占公司总股本为0.0099%。变动期间公司股价下跌3.3%,11月19日当日收盘报15.24元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000033409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","600557"],"gpt_icon":0},{"id":"2584903069","title":"甲流高发季催生市场需求,康缘药业金振口服液销量激增带动业绩突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2584903069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584903069?lang=zh_cn&edition=full","pubTime":"2025-11-20 10:05","pubTimestamp":1763604317,"startTime":"0","endTime":"0","summary":"文丨李振兴近日,康缘药业在投资者互动平台回应市场关切时明确表示,公司核心产品金振口服液凭借“儿童专用+疗效确切”的差异化优势,在本轮甲流疫情中销量实现显著增长,驱动公司业绩稳健增长。销量持续攀升拉动业绩增长康缘药业在回应中披露的经营数据显示,金振口服液的市场表现已成为公司业绩增长的“压舱石”。2025年以来,金振口服液的市场份额持续提升,带动公司业绩实现跨越式增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025112000007917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","600557","BK0188"],"gpt_icon":0},{"id":"2584582629","title":"11月18日增减持汇总:康缘药业增持 高德红外等15股减持(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584582629","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584582629?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:59","pubTimestamp":1763474340,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 据统计,11月18日,盘后康缘药业、超达装备、海大集团披露增持情况。包括立达信、艾布鲁、高德红外、嘉美包装、蕾奥规划、君逸数码、联合水务、亚翔集成、芯朋微、安旭生物、农心科技、禾川科技、世龙实业(维权)、中国化学、鸿泉技术在内的15家A股上市公司披露减持情况。\n\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-18/doc-infxvtuu5407955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0065","BK0121","002414","BK0037","BK0028","600557","BK0239","BK0214"],"gpt_icon":0},{"id":"2584933771","title":"康缘药业最新公告:实际控制人、董事肖伟增持公司股份2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933771","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584933771?lang=zh_cn&edition=full","pubTime":"2025-11-18 18:04","pubTimestamp":1763460281,"startTime":"0","endTime":"0","summary":"康缘药业(600557.SH)公告称,公司实际控制人、董事肖伟基于对公司未来发展的信心以及对公司长期投资价值的认可,近日通过上海证券交易所交易系统以集中竞价的方式,以自有资金增持公司股份20,000股,占公司总股本的0.0035%,累计增持金额325,200元(不含交易费用)。本次增持不触及权益变动报告义务,未导致公司控股股东及实际控制人发生变化。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800028463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2583598106","title":"每周股票复盘:康缘药业(600557)实控人一致行动人增持8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598106","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583598106?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:51","pubTimestamp":1763229069,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,康缘药业报收于16.39元,较上周的15.23元上涨7.62%。公司公告汇总:增持后实控人及其一致行动人持股比例升至36.6824%。股本股东变化股东增减持11月12日康缘药业发布公告,其股东赵诗文、肖立皓于2025年11月10日合计增持8.0万股,占公司目前总股本的0.0142%,变动期间该股股价上涨3.48%,截止11月10日收盘报15.76元。本次增持后,实际控制人及其一致行动人合计持有公司股份207,680,595股,占总股本的36.6824%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600557","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2582320818","title":"11月12日康缘药业发布公告,股东增持8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582320818","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582320818?lang=zh_cn&edition=full","pubTime":"2025-11-12 19:01","pubTimestamp":1762945279,"startTime":"0","endTime":"0","summary":"证券之星消息,11月12日康缘药业发布公告《康缘药业:江苏康缘药业股份有限公司关于实际控制人的一致行动人增持公司股份的公告》,其股东赵诗文、肖立皓于2025年11月10日合计增持8.0万股,占公司目前总股本的0.0142%,变动期间该股股价上涨3.48%,截止11月10日收盘报15.76元。股东增减持详情见下表:根据康缘药业2025年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200033688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600557","BK0028"],"gpt_icon":0},{"id":"2582086168","title":"每周股票复盘:康缘药业(600557)多名高管拟增持不低于12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582086168","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582086168?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:45","pubTimestamp":1762631116,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,康缘药业报收于15.23元,较上周的14.95元上涨1.87%。本周,康缘药业11月7日盘中最高价报15.42元。11月5日盘中最低价报14.75元。康缘药业当前最新总市值86.23亿元,在中药板块市值排名30/67,在两市A股市值排名2156/5166。本次增持不设价格区间,实施期间可能存在因市场变化导致计划延迟或无法完成的风险。增持主体在本次公告前6个月无减持情况,且承诺在增持期间及法定期限内不减持所持股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600557","BK0239"],"gpt_icon":0},{"id":"2581594002","title":"康缘药业(600557.SH)部分董高层拟合计增持不低于12万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2581594002","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581594002?lang=zh_cn&edition=full","pubTime":"2025-11-07 19:55","pubTimestamp":1762516554,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康缘药业(600557.SH)发布公告,公司董事兼总经理杨永春先生、董事高海鑫先生、董事陈学斌先生、副总经理刘权先生、副总经理王传磊先生、副总经理潘宇先生基于对公司未来发展的信心以及对公司长期投资价值的认可,计划自公告披露之日起1个月内,通过上海证券交易所交易系统以集中竞价的方式,以自有资金增持公司股份数量合计不低于12万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","600557","BK0239","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765450769623,"stockEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0866},{"period":"6month","weight":-0.0583},{"period":"1year","weight":0.0007},{"period":"ytd","weight":0.1153}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0065},{"period":"6month","weight":0.155},{"period":"1year","weight":0.1396},{"period":"ytd","weight":0.1637}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏康缘药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"40529人(较上一季度增加17.20%)","perCapita":"13969股","listingDate":"2002-09-18","address":"江苏省连云港市连云区经济技术开发区江宁工业城","registeredCapital":"56615万元","survey":" 江苏康缘药业股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是金振口服液、热毒宁注射液、杏贝止咳颗粒、温阳解毒颗粒、银杏二萜内酯葡胺注射液、天舒胶囊、天舒片、龙血通络胶囊、桂枝茯苓胶囊、散结镇痛胶囊、复方南星止痛膏、腰痹通胶囊、筋骨止痛凝胶、参乌益肾片、济川煎颗粒。公司是国家技术创新示范企业、国家重点高新技术企业、国家创新型试点企业、国家知识产权示范企业,全国制药工业百强企业。公司积极实施创新驱动战略,建立了国际先进的创新药物研发体系,在新药研发、有效发明专利、承担国家重大科研项目的数量上均居行业领先水平。","listedPrice":7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康缘药业(600557)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康缘药业(600557)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康缘药业,600557,康缘药业股票,康缘药业股票老虎,康缘药业股票老虎国际,康缘药业行情,康缘药业股票行情,康缘药业股价,康缘药业股市,康缘药业股票价格,康缘药业股票交易,康缘药业股票购买,康缘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康缘药业(600557)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康缘药业(600557)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}